Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Menu
Advanced
Wish Lists Wish Lists
Wish Lists Wish Lists
Wish Lists
Cart Cart
Cart Cart
Cart
Sign in
Sign in
Contact us
Advanced
Homepage > Company > Media > Pharma News > 2021

Pharma News, 2021

Relief for AZ, Amgen as FDA okays severe asthma hope tezepelumab
Relief for AZ, Amgen as FDA okays severe asthma hope tezepelumab
The FDA has approved AstraZeneca and Amgen’s severe asthma hope tezepelumab, exonerating the drugmakers’ decision to press ahead with a regulatory filing despite a failed phase 3 trial. ...
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisors
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisors
The EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying it was unconvinced by the data submitted for the drug. ...
Novavax's COVID vaccine becomes the fifth jab to be approved for use in the EU
Novavax's COVID vaccine becomes the fifth jab to be approved for use in the EU

It was given the green light by the bloc's drugs regulator, the European Medicines Agency (EMA), on Monday.

Xalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee
Xalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee
Xalud Therapeutics, a clinical-stage biotechnology company developing DNA delivery therapies using a non-viral platform, announced today that the United States Food and Drug Administration (FDA) ha...
Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia
Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia
Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, announced today that the U.S. Food and D...
FDA Approves Tarpeyo (budesonide) to Reduce Proteinuria in IgA Nephropathy
FDA Approves Tarpeyo (budesonide) to Reduce Proteinuria in IgA Nephropathy
Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release c...
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
AbbVie today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who...
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
Novartis today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s disease (HD).  ...
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ® / XELJANZ® XR (tofacitinib) for th...
Needle free COVID-19 vaccine trialled in UK
Needle free COVID-19 vaccine trialled in UK

The DIOSvax technology produced by the University of Southampton aims to predict how the virus could mutate.

Mount Sinai researchers present encouraging clinical trial results on novel therapy for bone marrow cancer
Mount Sinai researchers present encouraging clinical trial results on novel therapy for bone marrow cancer
Mount Sinai physician-scientists have found that a novel therapy for the bone marrow cancer myelofibrosis is safe and well-tolerated and is associated with modest improvements in patients in a Phas...
Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma
Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma
Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat cancers, announced today that the U.S. Food and D...
0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Screening Compounds
Building blocks
Inhibitors and approved drugs
Natural base
Virtual space
Drug Discovery Services
AI Kinome Profile
Al/ML Data sets
Synthetic and Medicinal Chemistry
In silico drug design (CADD)
Discovery biology
ADME, DMPK
Functional ex vivo and in vivo models
Safety and Toxicology
Company
News & Media
Contact us
Trends in discovery compounds

We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.

Accept